Investigational premature ejaculation therapy shows promise

A topical metered dose spray known as PSD502, under development for the treatment of primary premature ejaculation, appears to offer improvement in time to ejaculation, according to data presented at the AUA annual meeting in San Francisco.

Evaluating a combined total of 556 (randomized) and 536 (treated) men with primary PE in the United States, Canada, and Europe over a 3-month period, the data demonstrated that men who were treated with PSD502 5 minutes before intercourse by applying PSD502 to the glans penis via a topical metered dose spray had a time to ejaculation 5.5 times longer than those who used a placebo spray.

A co-primary endpoint also looked at ejaculatory control and satisfaction. Point differences of 6.0 and 5.3 were observed between the PSD502 group and placebo in ejaculatory control and satisfaction domains, respectively (p

"Combined results from the PSD502 pivotal studies are very exciting, and this is a significant milestone for men suffering from PE," said clinical trial investigator Ira D. Sharlip, MD, of the University of California, San Francisco.

Dr. Sharlip is an investigator for Shionogi Pharma, Inc.